Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer

Figures & data

Figure 1. Flow chart of patient selection.

Table 1. Baseline data.

	CHT	IM	p
Number	18	25
Age, median (IQR)^a	66.5 (16.5)	75 (14)	.035
Sex^a			1.000
Male	13	19
Female	5	6
T classification^a			.428
Ta	10	18
T1	8	7
EAU risk stratification^b			1.000
Intermediate	6	5
High	12	20
Bladder cancer history^b			<.001
Recurrence, n (%)	13 (72.2%)	0 (0%)
Treatment naïve, n (%)	5 (27.8%)	25 (100%)
Thermal dose, CEM43 (median)	9.12 (1.6–23.27)
Follow up time, median (IQR)^c	14 (16)	23 (6)	.482

CHT: chemohyperthermia; EAU: European Association of Urology; IM: intravesical mitomycin; IQR: interquartile range.

^aTested by Independent T test.

^bTested by Mann-Whitney U test.

^cTested by the reverse Kaplan-Meier method.

Figure 2. Kaplan-Meier method for recurrence-free survival rate (p: .028).

Table 2. Recurrence rate according to Treatment.

	CHT	IM	p^a
Recurrence rate at 12 months,%	11.1 (1.4–40.1)	44 (22–78.7)	.048
Recurrence rate at 24 months,%	11.1 (1.4–40.1)	48 (24.8–83.9)	.027

CHT: chemohyperthermia; IM: intravesical mitomycin.

^aTested by Chi-Square test.

Table 3. Adverse events of both groups.

	CHT	IM	p^a
Urinary frequency	12 (66.7%)	17 (68%)
Gross hematuria	2 (11.1%)	1 (4%)
Suprapubic soreness	2 (11.1%)	0 (0%)
Total	12 (66.7%)	17 (68%)	1.000

CHT: chemohyperthermia; IM: intravesical mitomycin.

^aTested by Chi-Square test.